Skip to content

Innate Pharma SA

IPHA IPHYF

CIK 0001598599

← back to feed
Revenue (TTM)
€9.01M
−55.2% YoY FY Dec 2025
Net Income (TTM)
−€49.18M
+0.6% YoY FY Dec 2025
EPS Diluted (TTM)
−€0.55
+9.8% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
-599.8%
FY Dec 2025
Net Margin
-546.1%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
€28.09M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
93.72M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings